Legal Featured Article
December 10, 2010
Public Review of NTP Patents Launched
By Calvin Azuri, TMCnet Contributor
Three new requests for research have been received by Article One Partners. According to an announcement made by Article One Partners, the focus of these patent studies is the patents held by NTP Incorporated. A $612 million settlement, which was a result of litigation against BlackBerry (News - Alert) maker Research-in-Motion, has made NTP famous.
The assertion of patent infringement has been expanded by NTP to other top players in the mobile and smartphone industry with new litigation. A request to research evidence predating the patent claims has been made to Article One Partners' global community of Researchers.
Since 2006, in separate cases, suits have been filed by NTP against 13 defendants. Related to the delivery of electronic mail over wireless communications systems, up to eight patents have been filed by NTP. A suit in the Eastern District of Virginia has been filed by NTP against Alltel (News - Alert) Corp.; Apple, Inc.; AT&T Mobility, LLC; Google, Inc.; and HTC Corp. Suit have also been filed against LG Electronics, Inc.; Microsoft Corp.; Motorola, Inc.; Palm, Inc.; Sprint Nextel Corp.; T-Mobile (News - Alert) USA, Inc.; Verizon Wireless; and Yahoo!, Inc.
At least $10,000 can be earned by researchers with Article One for each of the three studies. Active participation in the study and the AOP Community can help the researchers earn profit sharing points. Responses can also be submitted at the website.
The NTP Patent Studies can be reviewed by researchers here. Evidence of publicly available information predating a patent's invention is known as prior art. The patent claims are rendered obvious with this evidence. Published content anywhere in the world and in any language may be used as prior art knowledge.
Calvin Azuri is a contributing editor for TMCnet. To read more of Calvin’s articles, please visit his columnist page.
Edited by Tammy Wolf
LATEST LEGAL NEWS
Research and Markets: Heplisav: 1018 ISS Immunostimulatory Oligonucleotide with HBsAg (Prophylactic Hepatitis B Virus Vaccines) - Global Forecast and Market Analysis to 2022
Lieff Cabraser Reminds CytRx Corporation Investors of Upcoming Deadline in Class Action Litigation - CYTR
Amazon and HBO Ink Exclusive Multi-Year Deal to Bring Award-Winning HBO Programming to Prime Members